The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Early/Localized disease, Locally Advanced/Recurrent/Advanced disease, and Biology


Genitourinary Cancers

2009 Genitourinary Cancers Symposium

For a list of disclosures, please use the Disclosure links at the bottom of this page.
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


Sort by: title abstract no. first author  |  Search Abstracts

ABSTRACT TITLE FIRST AUTHOR     ABSTRACT NO.
The Selenium and Vitamin E Cancer Prevention Trial (SELECT): Southwest Oncology Group Study S0000.

E. A. Klein

1

Defining the α/β ratio for prostate cancer: Results of a randomized radiotherapy hypofractionation trial.

A. Pollack

4

Survival benefit with oral sodium clodronate in metastatic but not localised prostate cancer: Long-term results of MRC PR04 & PR05.

D. P. Dearnaley

6

A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC).

E. Small

7

The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: Validation in the Duke Prostate Center (DPC) database.

J. Jayachandran

11

Use of inhibitor of differentiation-1 (Id1) expression (exp) to discriminate good prognosis (GP) from poor prognosis (PP) prostate cancer (PCa).

I. Gil-Bazo

12

Clinical outcome of expectantly managed early prostate cancer: A comparison between tumors that do and do not fulfill the Epstein criteria for insignificant disease.

R. C. van den Bergh

14

A large prospective study linking fatty acid synthase polymorphisms to prostate cancer (PCa) tumor expression, risk, and survival.

P. L. Nguyen

31

The dimeric form of prostate-specific membrane antigen is expressed broadly in nonprostatic tumor neovasculature.

D. Ma

36

Prostate cancer detected by methylated gene markers GST-pi, RAR-2b, and APC in initially cancer-negative biopsies with subsequent positive biopsies.

D. Troyer

38

Utility of MRI spine for the staging of prostate cancer.

R. Venkitaraman

41

Use of pretreatment biomarker levels to improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.

S. Shariat

42

Effect of 11C-Choline PET for the detection of the site of recurrence in patients with PSA rise after radical prostatectomy.

A. J. Breeuwsma

43

Bcl-2 mediated modulation of vascularization in prostate cancer xenografts.

C. Rosser

46

Outcomes of untreated, localized prostate cancer with respect to serum and urinary cytokine concentrations.

H. E. O'Donnell

47

Lesion flare on bone scan in response to treatment of prostate cancer.

A. Horwich Professor

49

The association of obesity and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy.

L. L. BaƱez

53

Characterization of lymphoid infiltrates in prostatectomy specimens post neoadjuvant hormonal therapy using quantitative immunofluorescence and RNA FISH.

M. J. Donovan

54

Prognostic value of DNA content for unfavorable biopsy conversion free survival among men with low-grade, low-stage prostate cancer enrolled in an expectant management program.

S. Isharwal

55

Prognostic role of somatostatin receptor subtypes in human prostate cancer.

A. Gernone

56

Detection of prostate carcinoma with contrast-enhanced transrectal ultrasonography (CE-TRUS): Correlation of TRUS, targeted biopsies and whole-mount prostatectomy specimens in 27 patients.

J. C. Zola

57

A pilot study to determine correlation of positron emission tomography (PET), histopathology and PSA levels in prostate cancer (PC) patients (pts) undergoing neoadjuvant docetaxel chemotherapy.

I. D. Davis

58

Added value of MR-guided biopsies following repetitive negative TRUS-guided biopsies in the diagnosis of prostate cancer.

D. M. Somford

60

Use of ratio of serum pro-PSA to fraction serum free PSA to predict the need for treatment among men with low-grade, low- stage prostate cancer enrolled in an expectant management program.

D. V. Makarov

63

Influence of dietary ganglioside on prostate cancer biomarkers.

J. Miklavcic

64

A study of the reliability of molecular diagnostic markers in the detection and staging of prostate cancer aggressiveness: A Middle Eastern perspective.

M. Al-Maghrebi

65

Application of the functional diffusion map (fDM) to assess treatment response in metastatic prostate cancer (PCa).

D. Bradley

66

The impact of a multidisciplinary approach in the management of urologic malignancies: Does it influence diagnostic and treatment decisions?

R. Pruthi

68

Protein preserving fixative for matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS).

D. Troyer

69

Practical nomograms to predict total seed activity and dose-volume histogram parameters for I-125 permanent prostate brachytherapy.

T. Arimura

73

High-dose local irradiation to locally-advanced prostate cancer with intensity-modulated radiotherapy combined with neoadjuvant hormonal therapy.

T. Mizowaki

74

Modification of radiotherapy target volume and rectal dose by daily isocenter correction.

R. R. Rajendran

75

Active surveillance in low-risk prostate cancer patients: Preliminary analysis of variables associated to protocol drop out.

R. Valdagni

76

Image-guided radiotherapy (IGRT) for prostate cancer comparing fiducial markers with portal imaging and cone beam computed tomography (CBCT).

B. M. Barney

77

Preliminary results of a phase I trial of preoperative radiotherapy for high-risk localized prostate cancer.

B. F. Koontz

78

Differences in disease-free survival and acute toxicity between African-American and non-Latino white men with localized prostate cancer treated with intensity modulated radiation therapy.

S. Oh

79

Use of gold markers for setup in fractionated high dose rate brachytherapy as a monotherapy for prostate cancer.

P. Ghadjar

80

Spot scanning proton radiation therapy for prostate cancer: Treatment technique and dosimetric consequences of rotational and translational setup errors.

J. J. Meyer

81

A strategy to reduce post-implant morbidity following ultrasound-guided low-dose rate prostate brachytherapy.

A. E. Addesa

82

Virtual HDR prostate CyberKnife radiosurgery: PSA-response, toxicity and quality of life evaluation.

D. B. Fuller

83

Do margins matter? The prognostic significance of positive surgical margins (PSM) in radical prostatectomy (RP) specimens for prostate cancer-specific mortality (PCSM).

A. J. Stephenson

85

Influence of serum testosterone level and body mass index on survival in men treated with immediate compared with deferred androgen deprivation for node-positive prostate cancer after prostatectomy and pelvic lymphadenectomy.

E. A. Singer

87

Extent of androgen suppression on prostate cancer-specific mortality in men with localized or locally advanced prostate cancer treated with dose-escalated radiation therapy.

A. Nanda

88

Active surveillance for favorable risk prostate cancer: Long-term follow-up in 453 patients.

L. Klotz

89

A randomized study comparing quality of life after antiandrogens with or without radiotherapy in the treatment of locally advanced prostate cancer.

P. Fransson

90

Elderly men with high-risk prostate cancer and the risk of death following locoregional therapy with androgen suppression therapy.

K. E. Hoffman

92

Initial toxicity results of the phase III conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP) trial (ISRCTN97182923).

D. Dearnaley

94

Prostate-specific antigen recurrence after radical prostatectomy and the risk of death.

T. K. Choueiri

95

PSA kinetics less than 5 years after treatment with brachytherapy or external beam radiotherapy: Defining the long-term PSA profile for biochemical control.

J. P. Ciezki

96

Extent of lymphadenectomy and biochemical recurrence after RP: A multicenter study.

M. Lodde Sr.

97

Active surveillance for localized prostate cancer: What are the triggers for intervention?

J. Coen

98

Prostate-specific antigen velocity risk count for prediction of radical prostatectomy outcomes.

S. Loeb

99

Comparison of the biochemical recurrence rate between open and laparoscopic radical prostatectomy: 10-year experience.

K. Touijer

101

Neoadjuvant androgen suppression therapy (AST) prior to brachytherapy and risk of death in men with favorable risk prostate cancer and pre-existing cardiovascular comorbidity.

J. H. Hayes

102

Correlation with clinical failure using two different biochemical failure definitions.

K. Smith

104

Anxiety and distress during active surveillance for early prostate cancer.

R. C. van den Bergh

105

Use of 11C-Choline PET to detect site of recurrence in patients with PSA relapse after EBRT for prostate cancer.

A. J. Breeuwsma

106

Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies.

A. M. Joshua

107

A phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: Results of ECOG 9802.

R. S. DiPaola

108

Association of robotic prostatectomy with indications or referral for early postoperative radiation therapy.

J. P. Chino

109

Analysis of toxicity of whole-pelvis (WP) compared with prostate-only (PO) external beam radiotherapy for prostate cancer in the intensity-modulated radiotherapy/dose escalation era.

P. J. Rossi

110

Prognostic significance of lymphovascular invasion in radical prostatectomy specimens.

D. S. Yee

111

Hypofractionated radiation therapy for localized prostate cancer: McGill University experience with 66 Gy in 22 fractions.

N. J. Rene

112

Differences in quality of life (QoL) and patient satisfaction among patients from the COMPARE database undergoing hormonal therapy versus expectant management following PSA failure.

C. L. Bennett

113

A phase II clinical trial of single fraction high dose-rate brachytherapy and hypofractionated external beam radiotherapy in men with intermediate-risk carcinoma of the prostate.

G. Morton

114

Does time to biochemical recurrence following radical prostatectomy translate into worse outcomes?

M. B. Williams

115

Correlation of length of positive surgical margins and biochemical recurrence after radical prostatectomy.

I. M. van Oort

116

125Iodine brachytherapy (BT) as monotherapy in patients aged ≤55 years with localized prostate cancer.

A. Gomez-Iturriaga

117

Radiation dose escalation for localized prostate cancer: Intensity modulated radiation therapy compared with permanent transperineal brachytherapy.

W. Wong

118

The effect of androgen-deprivation therapy on CD4/CD8 T cells in HIV-negative patients receiving definitive 3D radiation treatment for their prostate carcinoma: A prospective study.

M. A. Elshaikh

119

Laparoscopic pelvic lymphadenectomy for clinically localized prostate cancer: A risk versus benefit analysis.

K. Touijer

120

Ultrasensitive PSA measurements using NADiA technology in men following radical prostatectomy (RP).

J. E. McDermed

121

Neoadjuvant androgen deprivation prior to salvage radiotherapy for biochemical relapse of prostate cancer after prostatectomy: A meta-analysis.

J. S. Tanguay MRCP, FRCR

122

Effect of leuprolide on serum beta amyloid levels in patients with prostate cancer with biochemical recurrence.

W. Tan

123

Updated outcomes of a prospective study of active surveillance of localised prostate cancer.

H. E. O'Donnell

125

Long-term follow up of post-prostatectomy cancer patients who had positive margins: Apparent overall survival benefit from adjunctive adjuvant radiation therapy.

R. O. Dillman

126

Genetic polymorphism association with hot flashes in prostate cancer patients initiated on androgen deprivation therapy (ADT).

M. Kohli

127

Permanent 125I prostate brachytherapy: 10-year clinical outcome in a large community-based program.

D. Linstadt

129

Effect of αvβ3 integrin and αvβ6 integrin on radioresistance of prostate cancer cells mediated through regulation of survivin.

T. Wang

130

Early results of a prospective trial comparing dose escalation with high-dose 3D-Conformal radiotherapy (HD-3D-CRT) or low-dose 3D-Conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B) for intermediate- or high-risk prostate cancer.

B. Guix

131

Single-fraction high-dose rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of localized prostate cancer.

F. L. Cury

132

Intensity-modulated radiotherapy (IMRT) with or without a simultaneous integrated boost on the intraprostatic lesion as primary therapy for prostate cancer: Report on acute toxicity.

P. Ost

133

Absence of late gastrointestinal toxicity for image guided prostate IMRT to 81Gy when the rectal V70Gy is limited to 10cc or less.

R. C. Nichols Jr.

134

Is computed tomography-based dosimetry one month after brachytherapy necessary when ultrasound-based, real-time intraoperative planning is applied?

H. Matzkin

135

Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy.

G. De Meerleer

136

Long-term outcomes for patients with prostate cancer having intermediate and high-risk disease treated with brachytherapy and supplemental conformal radiation.

M. J. Dattoli

137

The role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated IMRT.

D. Vesprini

138

Toxicity analysis of dose escalation from 75.6 Gy to 81.0 Gy in prostate cancer.

N. Xu

139

Long term results of salvage interstitial high-dose rate brachytherapy for local-only recurrent prostate cancer treated with definitive conventional external beam radiotherapy.

A. A. Pellizzon

140

Brachytherapy (BQT) rescue after external radiotherapy failure in prostate cancer patients. A multicenter Spanish experience.

I. Henriquez Lopez

141

Prognostic risk factors to predict final pathohistology in patients undergoing radical salvage prostatectomy for locally recurrent prostate cancer after radiation therapy.

A. Heidenreich

142

Predictors of the risk of androgen-independent progression after salvage radical prostatectomy for locally-recurrent prostate cancer following initial radiation therapy.

E. Chiong

143

The effect of Gleason grade 3 and 4 pattern-ratio for Gleason 7, intermediate risk, localized prostate cancer treated with iodine-125 monotherapy in Leeds over 10 years.

N. Munro

144

Long-term follow-up of salvage cryotherapy for locally-recurrent prostate cancer following initial radiation therapy.

E. Chiong

145

Dose-volume guidelines and late rectal toxicity after hypofractionated radiation therapy for prostate cancer.

S. Faria

146

Phase II study of treatment with 5-alpha reductase inhibitors in low risk prostate cancer.

M. Lodde Sr.

147

Marked improvement in biochemical disease-free survival curves among men treated with I125 brachytherapy utilizing two different dosimetry calculations: Pre- and intraoperative.

H. Matzkin

148

Study of interference between electromagnetic beacons and wireless MOSFET dosimeters.

Z. Su

149

A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC).

C. Higano

LBA150

Phase I-II study of MDV3100 in castration-resistant prostate cancer (CRPC).

H. I. Scher

151

A phase II study correlating the response to dexamethasone with serum levels of serum interleukin 8 and C-reactive protein in progressive castration resistant prostate cancer.

J. M. O'Sullivan

152

Biomarker analysis of circulating tumor cells in prostate cancer: Correlating response to taxanes—A pilot study.

B. P. Levy

153

A review of the patterns of docetaxel use for hormone refractory prostate cancer (HRPC) at the Princess Margaret Hospital.

S. N. Chin

154

Low-dose metronomic cyclophosphamide (CTX) plus celecoxib (C) and dexamethasone (DEX) in elderly patients (>78 years) with advanced castration resistant prostate cancer (CRPC).

A. Fontana

155

Effect of androgen deprivation therapy on 25-hydroxy vitamin D level in patients with prostate cancer.

M. K. Chadha

156

Pharmacodynamic (PD) study of pre-prostatectomy rapamycin in men with advanced localized prostate cancer (PC): Preliminary results of a Department of Defense Prostate Cancer Clinical Trials Consortium Trial.

A. J. Armstrong

157

Cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC).

J. J. Karakunnel

158

Abiraterone acetate plus prednisone in chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) patients not exposed to ketoconazole: Results of a multicenter phase II study.

C. J. Ryan

159

A phase II study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPC) refractory to docetaxel-based therapy.

A. L. Harzstark

160

Circulating tumor cells (CTC) in patients with metastatic castration resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy.

D. C. Danila

161

Survival benefit in docetaxel-refractory androgen independent prostate cancer (AIPC) patients receiving second-line satraplatin in the SPARC trial.

D. P. Petrylak

163

A phase I study of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody combined with docetaxel (T) in subjects with metastatic castration-resistant prostate cancer (CRPC).

G. R. Hudes

164

A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC) (CA180085).

E. Yu

165

Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy.

J. S. de Bono

166

Denosumab treatment of prostate cancer with bone metastases and elevated urine N-telopeptide levels after therapy with intravenous bisphosphonates: Results of a phase II randomized trial.

K. Fizazi

167

Pain interference scores at 6-weeks from baseline and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).

S. Halabi

168

Development of risk groups in metastatic castration-resistant prostate cancer (mCRPC) to facilitate identification of active chemotherapy regimens.

A. J. Armstrong

169

Randomized phase II trial of zoledronic acid on bone mineral density in patients with stage D prostate cancer undergoing androgen ablation therapy.

J. Lang

170

Intermittent versus continuous maximal androgen blockade in metastatic prostate cancer patients. A randomized trial.

N. Mottet

171

Phase I trial of fractionated-dose 177lutetium radiolabeled antiprostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC).

S. T. Tagawa

172

PATCH, a randomised phase II trial of oestrogen patches versus LHRH as first-line hormonal therapy for prostate cancer: Planned interim analysis results.

R. E. Langley

173

Phase Ib study of AGS-PSCA, an anti-PSCA human antibody, in castration-resistant prostate cancer (CRPC).

M. J. Morris

174

Phase II study of trabectedin in men with castration resistant prostate cancer (CRPC).

D. Michaelson

175

Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: A phase I/II study (CA180-086).

J. Araujo

177

A placebo-controlled, pase II sudy of ezastaurin combined with docetaxel (D) and prednisone (P), followed by enzastaurin maintenance in castrate, metastatic prostate cancer: Safety lead-in results.

R. Dreicer

178

Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel therapy in combination with zoledronic acid +/- strontium-89 in hormone-refractory prostate cancer patients. ISRCTN12808747.

N. D. James

180

Azacitidine for castration-resistant prostate cancer (CRPC) progressing on combined androgen blockade (CAB).

G. Sonpavde

181

Clinical significance of postchemotherapy PSA surge syndrome in patient with HRPC treated with docetaxel-based chemotherapy.

J. Lee

183

Phase I trial of PSA-TRICOM vaccine and ipilimumab in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC).

M. Mohebtash

184

Docetaxel retreatment as second- and third-line chemotherapy in metastatic hormone refractory prostate cancer patients pretreated with docetaxel: An updated analysis.

J. Ansari

185

Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of metastatic hormone refractory prostate cancer (HRPC).

R. Earhart

186

Candidate predictors of response to abiraterone acetate (AA) in castrate-resistant prostate cancer (CRPC).

E. Efstathiou

187

A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic, PSA relapse prostate cancer patients.

E. I. Heath

188

Phase II study of high-dose fenretinide for advanced or metastatic hormone-refractory prostate cancer.

M. M. Moore

189

Phase II trial of bevacizumab (B) with oral satraplatin (S) and prednisone in docetaxel-pretreated metastatic castrate resistant prostate cancer (CRPC).

U. N. Vaishampayan

190

Docetaxel every 21 days and imatinib for castrate resistant prostate cancer: A phase II trial.

T. L. Gillison

191

An exploratory analysis of the association between PSA Working Group I (PSAWG) progression and clinical progression (radiographic or symptomatic) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC) treated with a docetaxel-based regimen.

Y. M. Ning

192

Alterations of natural killer cells in metastatic prostate cancer.

C. Veuillen

193

Development of disulfiram as a novel DNMT1 inhibitor in prostate cancer.

J. Lin

194

Effect of lovastatin on human prostate cancer cell sensitivity to Adenoviral mediated TRAIL-induced apoptosis.

S. A. Ko

195

Effect of CTCE-9908 on apoptosis in xenograft prostatic tumors and knock down of Bcl-2.

C. Rosser

196

A large animal model for prostate cancer research mimicking the high-risk human disease.

F. L. Cury

197

Hormonal and chemotherapy effects on plasma VEGF-A and -D in prostate cancer patients.

M. Kohli

198

PTEN knockdown, DNA repair, and chemotherapy response in prostate cancer cell lines.

R. G. Bristow

199

Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel-refractory prostate cancer.

J. A. Reeves

200

Effect of proepithelin on prostate cancer cell biology: Cell growth, migration and anchorage-independent growth.

A. Morrione

201

Mouse prostate cancer is inhibited by disrupting murine telomerase: A new pre-clinical model.

T. Xu

202

A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer (HRPC).

R. Molife

203

Patient-reported outcomes of a randomized placebo-controlled phase II trial of the specific endothelin A receptor antagonist ZD4054 in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer.

N. Dawson

204

Cost effectiveness of zoledronic acid for the prevention of skeletal related events in prostate cancer patients with bone metastases in France.

M. F. Botteman

206

Phase II study of oral phenoxodiol in patients with castrate and non-castrate prostate cancer.

A. Elfiky

207

Docetaxel and gemcitabine (D&G) for treatment of castrate-refractory metastatic prostate cancer (CRMPC): A phase I/II trial.

T. Z. Buch-Hansen

208

Degarelix versus leuprolide treatment in patients with advanced prostate cancer (Pca): PSA failures during a randomized, phase III trial (CS21).

M. Gittelman

209

Comparing the overall survival of metastatic castration resistant prostate cancer patients treated with docetaxel, a vaccine admixed with one costimulatory molecule, and a vaccine with three costimulatory molecules.

R. A. Madan

210

Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen, and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.

H. J. Ananias

211

Presentation, treatment, and outcomes of dural metastases (DM) in men with metastatic castrate resistant prostate cancer (mCRPC): A case series.

A. J. Lawton

212

Docetaxel efficacy/toxicity in patients aged 70-85 years with metastatic prostate cancer.

D. R. Shepard

213

Cytokine changes in understanding toxicity to cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade in patients (pts) with castrate metastatic prostate cancer (PC).

J. Yuan

215

Curcumin analog, ASC-J9, kills prostate cancer cells independent of androgen receptor (AR) status.

J. Zhang

216

LIP-rMDVA+VRL composed of liposomal cDNA encoding recombinant multimodular proteins rMDVA comprising disintegrin/cysteine rich disulfide bond 2RGD, and C-terminal domain (ammodystatin), metalloprotease-domain (ammodylysin), and dimeric disintegrin/MLD-VGD domain (VADD) isolated from vipera ammodytes with VRL eradicated HRPC.

J. Giannios

217

Phase I trial of patupilone (P) and RAD001 (R) in patients (pts) with advanced solid tumors.

M. N. Stein

218

A single arm phase II trial of IPI-504 in patients with castration resistant prostate cancer (CRPC).

W. K. Oh

219

Role of androgen deprivation treatment in patients with castration-resistant prostate cancer receiving docetaxel chemotherapy.

J. Lee

220

Quality of life (QOL) of patients (pts) with hormone-refractory prostate cancer (HRPC). Results from a randomized phase II trial with docetaxel (D) ± estramustine (E).

O. Caffo

221

CCL2 induces common signaling pathways to promote survival in prostate cancer PC3 cells and breast cancer MDA-MB231 cells via survivin up-regulation.

A. S. Alva

222

Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration-resistant prostate cancer (CRPC): A phase II clinical trial with pharmacodynamic evaluation.

A. Fontana

223

Correlation of presence or absence of symptoms with survival in CRPC treated with docetaxel. Interim results of a pooled study from 4 UK centres.

A. Bahl

224

Health-related quality of life and patient-reported outcomes in metastatic androgen-independent prostate cancer trials: A systematic review.

G. A. Colloca

225

Association of immunohistochemical stains with Gleason score and PSA levels in D2 prostate cancer patients.

S. K. Gounder

226




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.